Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy With High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine.

Inclusion Criteria: * Patient with cerebral lymphoma B cell refractory or relapsed within 12 months after first-line chemotherapy with high-dose methotrexate (1.5 g / m²) and high dose cytarabine (2g / m²) and / or radiotherapy or autologous, or patient with an indication against these treatments. Refractory disease is defined by the absence of objective response to treatment or relapse within 3 months of it. A relapse is defined as disease progression after obtaining a complete or partial response. * Age greater than or equal to 18 years * Performance Index less than 4 * Illness measured by CT or MRI * Hematologic adequate: neutrophils\> 1.5 x 106 / L, platelets\> 100x106 / L * Adequate hepatic function: ALT / AST and bilirubin less than the upper limit of the normal laboratory * Adequate renal function: creatinine clearance greater than 60 ml / min * adequate cardiac function measured by ejection fraction of the left ventricle\> 50% by echocardiography * Informed consent signed * Negative pregnancy test for women of childbearing age * Able to understand the arrangements for monitoring the study and to comply * Corticosteroids are only accepted during the first cycle Exclusion Criteria: * Patients with immunosuppression from any cause (HIV, history of transplantation, immunosuppressive treatments ...) * Prior treatment MYOCET ® or other anthracycline * Active infection * Surgery large (more than 3 days hospitalization) within 28 days before enrollment in the study, except for a diagnostic neurosurgical * Hypersensitivity to any component of the treatment * Contraindications to the administration of MYOCET ® and / or dexamethasone Participation in a clinical trial within 4 weeks prior to study entry